Trial Profile
Six Month Safety Follow-up Study for PR-021 [Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Eosinophilic Esophagitis Subjects]
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Eosinophilic oesophagitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Adare Pharmaceuticals
- 08 Feb 2017 Status changed from recruiting to completed.